In a move that underscores the growing maturity of the Chinese biotech sector, Sichuan-based Haisco Pharmaceutical Group has entered into a significant licensing agreement with global pharmaceutical giant AbbVie. The deal centers on Haisco’s proprietary Nav1.8 inhibitor, a promising class of non-opioid analgesics designed to treat chronic and acute pain without the addictive properties associated with traditional painkillers. This partnership grants AbbVie exclusive rights to develop, manufacture, and commercialize the drug candidate across all global markets, excluding mainland China, Hong Kong, and Macau.
The financial structure of the agreement highlights the high stakes of the pain management market. Haisco is set to receive an immediate $30 million upfront payment, with the potential to earn an additional $715 million tied to various developmental and commercial milestones. Beyond these cash injections, AbbVie has committed to financing certain research and development costs as the Nav1.8 program progresses toward clinical proof-of-concept, mitigating the financial risks for the Chinese firm during the most volatile stages of drug development.
Nav1.8 inhibitors have become a focal point of intense pharmaceutical interest recently, as the global medical community seeks alternatives to opioids. These drugs work by targeting specific sodium channels in the peripheral nervous system, effectively blocking pain signals before they reach the brain. By acquiring Haisco’s candidate, AbbVie is positioning itself to compete in a field currently led by Vertex Pharmaceuticals, which recently reported positive late-stage data for its own Nav1.8 candidate, VX-548.
This transaction represents a broader trend of 'out-licensing' deals that are redefining the Chinese pharmaceutical landscape. Historically known for manufacturing generics, Chinese firms are increasingly being recognized as sources of primary innovation. For Haisco, the deal provides a massive infusion of non-dilutive capital and the prestige of a partnership with a Top 10 global pharma leader, while for AbbVie, it secures a strategic asset in a therapeutic area with significant unmet need.